Ophthalmic Biosimilars – Safe Biologics

Dr. McKibbin Presents Poster Session at DIA Global Annual Meeting 2023

July 20, 2023

On June 26th, ASBM Chairman Ralph McKibbin presented a poster at the DIA Global Annual Meeting in Boston, MA. The poster was based on the findings from ASBM’s Canadian ophthalmologist survey and compared the findings with those of other physicians surveyed in recent years. The surveys examined physician attitudes toward biosimilar substitution practices, pharmacovigilance and nomenclature standards, and different […]

ASBM’s Michael Reilly Participates in IFA’s Vision Health Month Webinar

May 15, 2023

On May 15th, ASBM Executive Director Michael Reilly participated in a webinar entitled Impact of Emerging Policies on the Vision of Older Canadians hosted by the International Federation on Ageing (IFA). As part of the celebration of the Vision Health Month, this webinar was executed to raise awareness on the importance of eye health, prevention of vision […]

GaBI Journal publishes Whitepaper on Canadian Ophthalmologist Survey

May 9, 2023

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). The paper is authored by IFA Secretary-General Jane Barratt and ASBM Executive Director Michael Reilly. The survey revealed that 81% […]

ASBM/IFA Survey: As Ontario Announces Forced Biosimilar Switching, Ophthalmologists Are Latest Specialty to Raise Concerns

February 28, 2023

Press Release: As Ontario Announces Forced Biosimilar Switching, Ophthalmologists Are Latest Specialty to Raise Concerns 28 February 2023 TORONTO, ONTARIO – Physicians and their patients- and not a government -should choose which biologic medicine to use, according to a new survey of Canadian ophthalmologists by the Alliance for Safe Biologic Medicines (ASBM) and the International […]

September 2022 Newsletter

October 24, 2022

EMA & HMA Declare All Biosimilars “Interchangeable”In a joint statement dated September 19th, 2022, the European Medicines Agency (EMA) and the Heads of Medicines Agencies declared that all biosimilars approved in the European Union are interchangeable with their reference medicines. According to the statement, “interchangeable” means “the biosimilar can be used instead of its reference product (or vice versa) or one biosimilar can […]

September 2022 Newsletter

October 24, 2022

GaBI Publishes Summary of ASBM Webinar on Biosimilar Success Factors The Generics and Biosimilars Initiative (GaBI) has published a report on the first of two webinars the organization recently co-hosted with ASBM. The report summarizes the presentations from the June 29th webinar which examined “Key Factors for Successful Biosimilar Uptake in Europe, Canada and the US”. View the webinar here. The […]

ASBM, IFA Observe World Sight Day 2022

October 13, 2022

World Sight Day is observed worldwide every year on the second Thursday of October. This World Health Organization-designated day falls on 13 October this year. The purpose of World Sight Day is to increase public awareness about blindness, vision impairment, vision care, and ocular issues. The WHO estimates that 1 billion people worldwide suffer from […]

ASBM, IFA Observe World Sight Day 2022

October 13, 2022

World Sight Day is observed worldwide every year on the second Thursday of October. This World Health Organization-designated day falls on 13 October this year. The purpose of World Sight Day is to increase public awareness about blindness, vision impairment, vision care, and ocular issues. The WHO estimates that 1 billion people worldwide suffer from […]

American Academy of Ophthalmology Statement on Biosimilar Substitution

October 6, 2022

AMERICAN ACADEMY OF OPHTHALMOLOGY“‘ POLICY STATEMENT The Use of Biosimilars in Ophthalmic Practice Background Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated approval pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA)-approved biological product.1 […]

American Academy of Ophthalmology Statement on Biosimilar Substitution

October 6, 2022

AMERICAN ACADEMY OF OPHTHALMOLOGY“‘ POLICY STATEMENT The Use of Biosimilars in Ophthalmic Practice Background Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated approval pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA)-approved biological product.1 […]